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Introduction
For early medical abortion, many reports recommend
oral administration of mifepristone (RU 486) 600 mg,
followed by oral administration of misoprostol 400 μg
36–48 hours later, which results in a 87–96.9% com-
plete abortion rate [1–4].
When orally administered, mifepristone is quickly
absorbed and reaches its peak serum concentration in
1–2 hours. With a half-life of 24–48 hours, mifepristone
is best administered orally once only. Studies also show
that the peak serum concentration of mifepristone is
more or less invariable for a dose that ranges between
100 and 800 mg [5,6]. Hence, many early medical abor-
tion regimens use a dose of 200 mg mifepristone [7].
Research has shown that vaginal administration of
misoprostol is characterized by slow absorption but long
duration of high serum concentration. Hence, vaginal
bioavailability of misoprostol is three times greater
than oral bioavailability of misoprostol; thus, vaginal
administration of misoprostol has a relatively higher
success rate of abortion than oral administration [8].
A recent study shows that the success rate of com-
plete abortion remains unchanged even if the interval
between administration of mifepristone and subsequent
administration of misoprostol decreases from 36–48
hours to 6–8 hours [9]. Also, research reveals that the
therapeutic effect is good when the two drugs are used
concurrently. We studied the efficacy of mifepristone
and misoprostol used concurrently for early medical
abortion.
Materials and Methods
Between October 2005 and September 2006, a total of
90 early pregnant women requested medical abortion.
The program had the approval of the ethics committee
of Kuo General Hospital, Tainan, Taiwan.
Before receiving medical abortion, a patient had to
meet the following criteria: (1) patient requests med-
ical abortion; (2) gestational age ≤ 49 days, as con-
firmed by vaginal ultrasonography; (3) patient signs
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an agreement of consent and is informed of the advan-
tages and risks of medical abortion and the necessity
of receiving surgical abortion in case of medical abor-
tion failure; and (4) patient promises to attend follow-
up appointments.
No medical abortion was performed on pregnant
women with any of the following: (1) allergy to mifepri-
stone or prostaglandins; (2) symptoms of threatened
abortion; (3) medical history of diseases related to the
heart, respiratory system, kidneys, liver, or adrenal gland;
(4) medical history of thromboembolism, hyperten-
sion, coagulopathy, or diabetes mellitus; (5) medical
history of ultrasonographic or uterine pathology; and
(6) active pelvic infection.
Three clinic visits were scheduled. At visit 1 (day 1),
each female patient concurrently received oral mifepri-
stone 200 mg and vaginal administration of misopros-
tol 800 μg (in the form of four 200 μg tablets), and
stayed in the hospital for 1 hour of observation before
being discharged. Participants were given three 500 mg
tablets of acetaminophen that they could take every 
6 hours if they had lower abdominal pain.
At visit 2 (day 4), patients visited the hospital again
for transvaginal ultrasonography. Patients were instruct-
ed to be alert to the expulsion of the conceptus and 
to note the amount of bleeding. All symptoms, such as
abdominal pain, shivering, vomiting, nausea, headache,
diarrhea or other symptoms, were to be recorded. If a
patient had menses as usual or complained of menor-
rhagia, and the gestational sac was no longer visible
on ultrasound, the patient was scheduled to visit the
hospital 10 days later. If the gestational sac was intact,
surgical abortion was recommended, and the patient
received gynecologic examination when necessary.
At visit 3 (day 14), the patient was asked if she had
had bleeding, and underwent transvaginal ultrasonogra-
phy again. Normal ultrasonographic findings indicated
the end of therapy, but a follow-up appointment in 
1 week was made when necessary. The definition of a
successfully induced complete medical abortion was one
that occurred without surgery to evacuate the uterus.
At the end of therapy, patients filled out a question-
naire designed to determine whether they agreed that the
medical abortion was performed to their satisfaction;
the questionnaire consisted of multiple choice questions
with the following choices: strongly disagree; disagree;
neutral; agree; strongly agree.
Results
The mean age of the 90 women was 23.6 years (range,
17–42 years), and the mean gestational age was 44.8
days (range, 36–49 days); 50 (55.6%) were nulliparous,
16 (17.8%) were primiparous, and 24 (26.7%) were
multiparous. A total of 88 (97.8%) patients had com-
plete abortion; two (2.2%) had incomplete abortions
and received dilatation and curettage to evacuate the
uterus. The mean induction to abortion interval was
5.5 hours (range, 4–8 hours). The mean duration of
bleeding was 11.8 days (range, 9–32 days).
Side effects included abdominal pain in 56.7% (51
women), nausea in 17.8% (16), fever in 15.6% (14), shiv-
ering in 14.4% (13), headache in 13.3% (12), diarrhea
in 8.9% (8), and vomiting in 4.4% (4), and were mostly
mild and required no medication except for anal-
gesics. No patient had infection, severe hemorrhage or
any need for blood transfusion. Regarding how much
patients agreed that the therapy they had received were
performed to their satisfaction, the following answers
were received: strongly agree 72.2% (65 women), agree
18.9% (17), neutral 6.7% (6), disagree 2.2% (2); result-
ing in a satisfaction rate of 91.1% (82 patients).
Discussion
To achieve medical abortion, patients typically take
misoprostol 36–48 hours after taking mifepristone.
We evaluated the effects of taking the two drugs simul-
taneously, wherein vaginal administration of miso-
prostol resulted in a 97.8% success rate of complete
abortion with side effects similar to those previously
reported, and a high satisfaction rate of 91.1%.
As affirmed by many studies, administration of higher
doses of mifepristone within the range 100–800 mg
does not increase the serum peak concentration of
mifepristone. The reason for this is as follows: the
serum kinetics of mifepristone in humans is regulated
by the transport protein α1 acid glycoprotein (AAG),
and the saturation of the binding capacity of serum
AAG might explain the similar levels of serum concen-
trations of mifepristone after doses exceeding 100 mg
[7]. There is no difference between administration of
600 mg and 200 mg of mifepristone in terms of the
success rate of complete abortion [7]. Hence, we used
200 mg of mifepristone.
Since vaginal bioavailability of misoprostol is three
times greater than oral bioavailability of misoprostol,
vaginal administration of misoprostol is more effica-
cious than oral administration. Citing several papers,
Kahn et al assert that oral administration of misopros-
tol has an incomplete abortion rate of 6.4%, while the
rate for vaginal administration is 2.1% [3]; thus, vagi-
nal administration of misoprostol is more efficacious
than oral administration. Accordingly, we also adopted
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vaginal administration of misoprostol, and used 800 μg
as recommended in the literature.
The success rate of complete abortion will remain
unchanged even if the interval between administration
of mifepristone and subsequent administration of miso-
prostol decreases from 36–48 hours to 6–8 hours [9].
Insomuch as a shorter interval of administration of
mifepristone and subsequent administration of miso-
prostol is an available option, and considering that
vaginal administration of misoprostol results in strong
uterine contractions, the vaginal administration of miso-
prostol alone is crucial to a high success rate of com-
plete abortion. However, studies have indicated that the
combined use of mifepristone and misoprostol leads
to a higher success rate of abortion than with miso-
prostol alone. Jain et al, in a randomized double-blind
controlled trial, studied 250 pregnant women (gesta-
tional age < 56 days) [10]. Group 1 women received
mifepristone and vaginal administration of misopros-
tol 800 μg, and Group 2 women received vaginal
administration of misoprostol 800 μg only. Group 1
had a successful abortion rate of 95.7% (114/119),
and Group 2 had a successful abortion rate of 88.0%
(110/125); the difference was statistically significant
(p < 0.05). Therefore, we also used both mifepristone
and misoprostol.
In 2005, Murthy et al reported that in 40 women
with pregnancies < 7 gestational weeks who received
oral mifepristone 200 mg and vaginal administration
of misoprostol 800 μg, a complete abortion rate of
98% was achieved in 2 weeks, with only one woman
requiring suction and curettage because of incomplete
abortion [11]. Their conclusion was that combined
administration of mifepristone and misoprostol to preg-
nant women < 7 gestational weeks is an efficacious
way of achieving medical abortion. Our rate of 97.8%,
achieved with the same dosages, is similar to that of
Murthy et al’s.
Also in 2005, Schreiber et al studied 40 pregnant
women in their 8th gestational week (Group 1) and 40
pregnant women in their 9th gestational week (Group 2)
who received oral mifepristone 200 mg and vaginal
administration of misoprostol 800 μg, and who under-
went vaginal ultrasonography 24 hours and 2 weeks
afterwards [12]. They found that by the second week,
the success rates of complete abortion were 93% and
90% in Groups 1 and 2, respectively. They concluded
that mifepristone and misoprostol are efficacious in
women with pregnancies of 8–9 gestational weeks,
whether administered concurrently or one after the other
36–48 hours later. However, these results are slightly
unsatisfactory when compared to those of Murthy et al
[11], because Schreiber et al’s study involved pregnant
women at 50–56 days’ gestation (8 weeks) and 57–63
days’ gestation (9 weeks), compared to < 49 days’ ges-
tation in Murthy et al’s study.
More recently, in 2006, Kapp et al studied the effects
of oral mifepristone 100 mg and vaginal administra-
tion of misoprostol 800 μg in 39 pregnant women at
56 days’ gestation (9th gestational week), who received
follow-up consultation 2–7 days and phone-based
evaluation of symptoms and acceptability 3 weeks
afterwards [13]. The success rate of complete abortion
was 90%, and four women needed uterine aspiration.
Abortion occurred at a mean of 7 hours after taking the
drugs. Most of the participants (92%) considered it appro-
priate to take all the drugs during a single consultation
visit.
In conclusion, for medical abortion, women in their
7th week of gestation or earlier can receive oral mifepri-
stone and vaginal administration of misoprostol 800 μg
concurrently; the rate of successful abortion is high,
although an insight into the optimal timing, method
of administration, and dosage of misoprostol can only
be gained by further research.
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